Cargando…
SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis
SETD2, a H3K36 trimethyltransferase, is the most frequently mutated epigenetic modifier in lung adenocarcinoma, with a mutation frequency of approximately 9%. However, how SETD2 loss of function promotes tumorigenesis remains unclear. Using conditional Setd2-KO mice, we demonstrated that Setd2 defic...
Autores principales: | Xie, Yuchen, Sahin, Merve, Wakamatsu, Toru, Inoue-Yamauchi, Akane, Zhao, Wanming, Han, Song, Nargund, Amrita M., Yang, Shaoyuan, Lyu, Yang, Hsieh, James J., Leslie, Christina S., Cheng, Emily H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977508/ https://www.ncbi.nlm.nih.gov/pubmed/36810256 http://dx.doi.org/10.1172/jci.insight.154120 |
Ejemplares similares
-
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes
por: Xie, Yuchen, et al.
Publicado: (2022) -
Epigenotype–genotype–phenotype correlations in SETD1A and SETD2 chromatin disorders
por: Lee, Sunwoo, et al.
Publicado: (2023) -
Chromatin associated SETD3 negatively regulates VEGF expression
por: Cohn, Ofir, et al.
Publicado: (2016) -
A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation
por: Javaid, Hira, et al.
Publicado: (2023) -
SETD2: from chromatin modifier to multipronged regulator of the genome and beyond
por: Molenaar, Thom M., et al.
Publicado: (2022)